Authors' objectives: Sugammadex (SUG) is indicated for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide during surgery. SUG selectively binds to neuromuscular blocking agents, thereby preventing further attachment of the NMB agents to acetylcholine receptors and facilitating the return of muscle function. SUG may provide complete reversal of NMB regardless of the level of blockade. Controversy: The comparative effectiveness and safety of SUG relative to NEO has not yet been established, and questions remain regarding whether use of SUG results in improvements in quality-of-life (QOL) and functional outcomes. In addition, the potential benefits of SUG may not be sufficient to offset its high cost. Relevant Questions: How does SUG compare with NEO with regard to reversal of NMB following surgery? How does SUG compare with NEO with regard to safety for patients following surgery? How does SUG compare with NEO with regard to functional and QOL outcomes? Have definitive patient selection criteria been established for SUG?

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=56546

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc